Invesco Ltd. Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Invesco Ltd. lifted its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 4.1% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 371,767 shares of the company’s stock after acquiring an additional 14,559 shares during the period. Invesco Ltd. owned approximately 0.65% of Structure Therapeutics worth $10,082,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. grew its position in Structure Therapeutics by 230.0% during the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company’s stock worth $23,936,000 after purchasing an additional 380,115 shares during the last quarter. Handelsbanken Fonder AB acquired a new position in shares of Structure Therapeutics in the 4th quarter valued at $4,475,000. CCG Wealth Management LLC purchased a new position in Structure Therapeutics in the 4th quarter worth $4,068,000. Exome Asset Management LLC acquired a new stake in Structure Therapeutics during the 3rd quarter worth about $5,274,000. Finally, Candriam S.C.A. grew its stake in Structure Therapeutics by 59.6% during the 4th quarter. Candriam S.C.A. now owns 215,421 shares of the company’s stock valued at $5,842,000 after purchasing an additional 80,421 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of GPCR stock opened at $23.04 on Wednesday. The stock has a 50 day simple moving average of $20.18 and a 200-day simple moving average of $28.14. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -31.13 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on GPCR. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating for the company. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Tuesday. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.